A Landmark Collaboration Ushers in GlycoMIRAI at Nagoya University
In a significant boost to international scientific partnerships, Nagoya University and France's National Centre for Scientific Research (CNRS) have launched GlycoMIRAI, a pioneering International Research Laboratory (IRL) dedicated to glycoscience. Formally known as Multidisciplinary International Research for Advancing Innovation in Glycosciences, the lab's agreement was signed on April 1, 2026, at the French ambassador's residence in Tokyo by Nagoya University President Naoshi Sugiyama and CNRS Chairman Antoine Petit. A commemorative ceremony followed on April 14, 2026, at Nagoya University, marking the official kickoff for Japan's research community.Nagoya University's announcement
This initiative represents CNRS's highest-tier overseas collaboration, with GlycoMIRAI being the first IRL worldwide focused solely on glycoscience—the study of glycans, complex sugar chains that coat cell surfaces and play pivotal roles in biological processes. Directed by CNRS Senior Researcher Yann Guérardel from the University of Lille's Unit for Structural and Functional Glycobiology (UGSF), and with Deputy Director Chihiro Sato from Nagoya University's Institute for Glyco-core Research (iGCORE), the lab bridges complementary expertise from both nations.
For Nagoya University, a powerhouse in biosciences with six Nobel laureates since 2001, GlycoMIRAI elevates its global standing in higher education research. It expands ongoing ties with French researchers, fostering student exchanges, joint grants, and access to cutting-edge facilities on both sides of the collaboration.
What Are Glycans and Why Do They Matter in Modern Science?
Glycans, also called carbohydrates or sugar chains, are polysaccharides or oligosaccharides attached to proteins (glycoproteins) or lipids (glycolipids) on cell surfaces. Unlike DNA or proteins, which have linear sequences, glycans form branched structures, creating immense diversity—over 1 trillion possible combinations from just 60 building blocks. They mediate cell-cell recognition, immune responses, pathogen adhesion, and signaling pathways.
In medicine, glycans are game-changers. Aberrant glycan expression drives cancer metastasis, as tumor cells exploit them to evade immunity or invade tissues. In infections, viruses like influenza bind sialic acid-containing glycans to enter cells. Neurological disorders, such as Alzheimer's, involve glycan dysregulation in brain regeneration. Japan's Human Glycome Atlas Project (HGA), housed at iGCORE, catalogs human glycans to unlock diagnostics and therapies.
Glycoscience lags behind genomics due to analytical challenges—glycans don't amplify like DNA. GlycoMIRAI addresses this with advanced synthesis, imaging, and structural tools, promising breakthroughs in personalized medicine.
Nagoya University's iGCORE: The Foundation for Glycoscience Excellence
Central to GlycoMIRAI is Nagoya's iGCORE, established in 2021 under the Tokai National Higher Education and Research System (THERS) with Gifu University. This integrative institute unites over 60 researchers in glycan synthesis, imaging, biology, and medicine. Key facilities include cooperative labs for structural analysis and systems biology.
Under leaders like Professor Kenji Kadomatsu (Vice President, Nagoya) and Hiromune Ando (iGCORE Director, Gifu), iGCORE drives HGA and J-GlycoNet, Japan's national glycan network. Achievements include blood-based schizophrenia diagnostics via acidic glycans and polysialic acid studies linking to brain diseases.iGCORE overview
Chihiro Sato, iGCORE Professor and iGMED Director, exemplifies expertise. Her work on sialic acids—terminal glycan sugars in neural development and cancer—has yielded protocols for labeling and analysis, positioning Nagoya as Asia's glycoscience hub.
Deepening France-Japan Ties: From Symposia to a World-First IRL
France and Japan share decades of science diplomacy, with CNRS operating 15 IRLs in Japan—the most globally. Prior iGCORE-CNRS collaborations included joint papers, symposia, and exchanges. GlycoMIRAI formalizes this, enabling bilateral funding and mobility.
CNRS, with 1,100+ labs, brings structural glycobiology prowess from UGSF (Lille), led by Guérardel. His research on zebrafish glycomics and fungal glycans complements Sato's neural focus, creating synergies in marine biodiversity and neurodegeneration.
This partnership aligns with Japan's Moonshot R&D for glycan atlases and France's Horizon Europe ties, signaling higher education's role in bilateral innovation.
Photo by Manuel Cosentino on Unsplash
Core Research Pillars: Tackling Global Health Challenges
GlycoMIRAI targets four themes:
- Molecular Biodiversity: Marine glycans for novel biomaterials and drugs, leveraging Japan's ocean resources.
- Infection Mechanisms: Glycan-pathogen interactions for anti-infectives, vital post-COVID.
- Neural Dynamics: Glycans in regeneration vs. neurodegeneration, eyeing Alzheimer's therapies.
- Metabolic Insights: Glycan defects in diabetes/obesity for diagnostics.
Step-by-step: Identify glycan structures via mass spec/NMR, synthesize mimics, test in models, translate to therapies. Examples: Glyco-nanovaccines for cancer immunotherapy from Japanese labs show glycan-peptide synergy boosting immunity.
Empowering the Next Generation: Training and Career Opportunities
For students, GlycoMIRAI opens exchanges, dual supervision, and grants. Nagoya's graduate programs in bioagriculture and biotech gain French perspectives, enhancing employability in pharma/biotech.
In Japan, glycoscience jobs surge: postdocs at iGCORE earn ~¥5-7M/year, professors ¥10-15M. International labs like this attract global talent, aligning with MEXT's internationalization push. Sato's mentorship on sialic acid protocols equips trainees for industry roles at firms like Seikagaku.
Cultural context: Japan's collectivist research fosters teamwork; France adds creative structural biology, ideal for diverse teams.
Implications for Medicine: From Diagnostics to Vaccines
GlycoMIRAI accelerates applications:
- Cancer: Glycans as biomarkers/vaccine targets; Japan's peptide vaccines target glycan-altered tumors.
- Vaccines: Sialidase inhibitors block flu binding.
- Neuro: Polysialic acid restores neural plasticity.
Real-world: iGCORE's glycan blood test for schizophrenia (95% accuracy) previews metabolic diagnostics. Stats: Glycans in 80% immune events; cancer glyco-alterations in 70% cases.
Stakeholder Perspectives: Voices from Leaders
"GlycoMIRAI harnesses French-Japanese expertise on societal challenges," says Guérardel. Kadomatsu emphasizes iGCORE's expansion: "Unique facilities meet French innovation." Sugiyama hails it as THERS milestone.
Challenges: Glycan complexity demands interdisciplinary skills; solutions via joint training. Multi-perspective: French structural focus + Japanese functional biology.
Japan's Glycoscience Momentum: Policy and Investments
Japan invests ¥10B+ in HGA/J-GlycoNet, with 100+ labs. Nagoya leads via iGCORE's symposia (e.g., Glyco-Core 2025). GlycoMIRAI fits MEXT's global hubs, boosting uni rankings (Nagoya QS top 100 biosciences).
Impacts: 20% rise in glyco-papers from Japan 2020-2026; patents up 15%.
Future Outlook: Milestones and Global Influence
Short-term: Inauguration events, first exchanges. Long-term: Glycan therapeutics by 2030, HGA completion. For higher ed, more IRLs position Japanese unis as collab leaders.
Actionable: Aspiring researchers—apply iGCORE postdocs; unis—emulate Nagoya's model. GlycoMIRAI heralds a sweeter future for science.